Gastric cancer

Details

Review Type: Rapid

As per requests from jurisdictions, this project will be combined with PH0061 to be delivered together in order to streamline the process and work. Please refer to the project timelines for PH0061.

bulevirtide

Details

Key Milestones2
Call for patient/clinician input open22-Jan-25
Call for patient/clinician input closed18-Mar-25
Submission received09-Apr-25
Submission accepted25-Apr-25
Review initiated28-Apr-25
Draft CADTH review report(s) provided to sponsor for comment11-Jul-25
Deadline for sponsors comments22-Jul-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-Aug-25
Expert committee meeting (initial)27-Aug-25
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedback18-Sep-25
End of feedback period03-Oct-25

odevixibat

Details

Key Milestones2
Call for patient/clinician input open20-Jan-25
Call for patient/clinician input closed18-Mar-25
Submission received28-Feb-25
Submission accepted19-Mar-25
Clarification:

- Submission was not accepted for review on 17 Mar 2025

Review initiated20-Mar-25
Draft CADTH review report(s) provided to sponsor for comment05-Jun-25
Deadline for sponsors comments16-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor11-Jul-25
Expert committee meeting (initial)23-Jul-25
Draft recommendation issued to sponsorAugust 05, 2025
To
August 07, 2025
Draft recommendation posted for stakeholder feedback14-Aug-25
End of feedback period28-Aug-25

mirikizumab

Details

Key Milestones2
Call for patient/clinician input open16-Jan-25
Call for patient/clinician input closed18-Mar-25
Submission received04-Mar-25
Submission accepted19-Mar-25
Review initiated20-Mar-25
Draft CADTH review report(s) provided to sponsor for comment06-Jun-25
Deadline for sponsors comments17-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor11-Jul-25
Expert committee meeting (initial)23-Jul-25
Draft recommendation issued to sponsorAugust 05, 2025
To
August 07, 2025
Draft recommendation posted for stakeholder feedback14-Aug-25
End of feedback period28-Aug-25

mirvetuximab soravtansine

Details

Key Milestones2
Call for patient/clinician input open17-Jan-25
Call for patient/clinician input closed18-Mar-25
Submission received03-Mar-25
Submission accepted18-Mar-25
Review initiated19-Mar-25
Draft CADTH review report(s) provided to sponsor for comment13-Jun-25
Deadline for sponsors comments24-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor31-Jul-25
Expert committee meeting (initial)13-Aug-25
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedback04-Sep-25
End of feedback period18-Sep-25